Article · Wikipedia archive · Last revised Jul 31, 2026

Pelanserin

Pelanserin (developmental code name TR-2515) is a serotonin 5-HT2 and α1-adrenergic receptor antagonist which was under development for the treatment of hypertension but was never marketed. Its development was discontinued in 2001.

Last revised
Jul 31, 2026
Read time
≈ 2 min
Length
526 w
Citations
18
Source
Wikipedia ↗
Pelanserin
Clinical data
Other namesTR2515; TR-2515
Routes of
administration		Oral1
Drug classSerotonin 5-HT2A receptor antagonist; α1-Adrenergic receptor antagonist
ATC code
  • None
Pharmacokinetic data
Onset of action<1 hour (TmaxTooltip time to peak levels)1
Elimination half-life3.8 hours1
Identifiers
  • 3-[3-(4-phenylpiperazin-1-yl)propyl]quinazoline-2,4(1H,3H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H24N4O2
Molar mass364.449 g·mol−1
3D model (JSmol)
  • C1CN(CCN1CCCN2C(=O)C3=CC=CC=C3NC2=O)C4=CC=CC=C4
  • InChI=1S/C21H24N4O2/c26-20-18-9-4-5-10-19(18)22-21(27)25(20)12-6-11-23-13-15-24(16-14-23)17-7-2-1-3-8-17/h1-5,7-10H,6,11-16H2,(H,22,27)
  • Key:WPKPLSFHHBBLRY-UHFFFAOYSA-N

Pelanserin (developmental code name TR-2515) is a serotonin 5-HT2 and α1-adrenergic receptor antagonist which was under development for the treatment of hypertension but was never marketed.23 Its development was discontinued in 2001.2

Pharmacology

Pharmacokinetics

The pharmacokinetics of pelanserin have been studied.4 It has a relatively short elimination half-life.54 The drug's time to peak levels was less than 1 hour and its half-life was 3.8 hours in a single subject in an analytical study.1

Chemistry

Synthesis

Synthesis of pelanserin source ↗

Pelanserin (3) can be synthesized by a reaction between isatoic anhydride (1) and 1-(3-aminopropyl)-4-phenylpiperazine (2) in the presence of phosgene.678910111213

See also

See also

References

References

  1. Flores-Murrieta FJ, Hong E, Castañeda-Hernández G (June 1988). "Sensitive high-performance liquid chromatographic assay of pelanserin, a novel antihypertensive agent, in plasma samples". Journal of Chromatography. 428 (1): 167–172. doi:10.1016/s0378-4347(00)83903-1. PMID 3170670.
  2. "Pelanserin". AdisInsight. 30 August 2002. Retrieved 17 January 2026.
  3. Villalobos-Molina R, Ibarra M, Hong E (April 1995). "The 5-HT2 receptor antagonist, pelanserin, inhibits alpha 1-adrenoceptor-mediated vasoconstriction in vitro". European Journal of Pharmacology. 277 (2–3): 181–185. doi:10.1016/0014-2999(95)00074-u. PMID 7493607.
  4. Flores-Murrieta FJ, Herrera JE, Castañeda-Hernández G, Hong E (1992). "Pharmacokinetics of pelanserin in healthy volunteers". Proceedings of the Western Pharmacology Society. 35: 113–116. PMID 1502209.
  5. Espinoza R, Hong E, Villafuerte L (May 2000). "Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets". International Journal of Pharmaceutics. 201 (2): 165–173. doi:10.1016/s0378-5173(00)00406-3. PMID 10878323. Pelanserin is a weakly basic experimental drug with a short half-life and a prolonged release formulation was developed using hydroxypropyl methylcellulose (HPMC) and citric acid to set up a system bringing about gradual release of this drug.
  6. Hayao S, Havera HJ, Strycker WG, Leipzig TJ, Kulp RA, Hartzler HE (November 1965). "New sedative and hypotensive 3-substituted 2,4(1H,3H)-quinazolinediones". Journal of Medicinal Chemistry. 8 (6): 807–815. doi:10.1021/jm00330a017. PMID 5885076.
  7. Havera HJ, Vidrio H (December 1979). "Derivatives of 1,3-disubstituted 2,4(1H,3H)-quinazolinediones as possible peripheral vasodilators or antihypertensive agents". Journal of Medicinal Chemistry. 22 (12): 1548–1550. doi:10.1021/jm00198a024. PMID 231656.
  8. Garcia JD, Somanathan R, Rivero IA, Aguirre G, Hellberg LH (2000). "Synthesis of Deuterium-Labeled Antihypertensive 3-(4-Phenyl-1′-Piperazinyl)-Propyl-2,4-Quinazolinedione". Synthetic Communications. 30 (15): 2707–2711. doi:10.1080/00397910008086895.
  9. Li X, Lee YR, Kim SH (2011). "Concise Synthesis of Pelanserine, Goshuyuamide II, and Wuchuyuamide II with Quinazolinedione Nuclei". Bulletin of the Korean Chemical Society. 32 (9): 3480–3482. doi:10.5012/bkcs.2011.32.9.3480.
  10. Cortez R, Rivero IA, Somanathan R, Aguirre G, Ramirez F, Hong E (1991). "Synthesis of Quinazolinedione Using Triphosgene". Synthetic Communications. 21 (2): 285–292. doi:10.1080/00397919108020823.
  11. AT 269143B, "Verfahren zur Herstellung von neuen Chinazolindionderivaten und ihrer Säureadditionssalze bzw. ihrer entsprechenden Piperaziniumverbindungen [Process for the preparation of new quinazolinedione derivatives and their acid addition salts or their corresponding piperazinium compounds]", published 1969-03-10, assigned to Miles Laboratories, Inc. 
  12. US 3274194, Shin H, "Quinazolinedione derivatives", issued 20 September 1966, assigned to Bayer Corp. 
  13. US 3919425, Vidrio H, "Method of producing vasodilation using certain 3-substituted-quinazoline derivatives", issued 11 November 1975, assigned to Bayer Corp.